MODIFIED FIBROBLAST GROWTH FACTOR 1 (FGF-1) POLYPEPTIDES WITH INCREASED BINDING AFFINITY FOR HEPARIN AND ASSOCIATED METHODS
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Mar 25, 2021
app pub date -
Sep 2, 2020
filing date -
Dec 3, 2014
priority date (Note) -
Published
status (Latency Note)
Importance
Abstract
A modified FGF-1 polypeptide that has an increased binding affinity for heparin relative the wild-type human FGF-1's binding affinity for heparin is described. The modified FGF-1 polypeptide has at least 80% amino acid sequence identity to wild-type human FGF-1 having SEQ ID NO: 1. The serine at an amino acid position of the modified FGF-1 polypeptide corresponding to amino acid position 116 of SEQ ID NO: 1 is substituted by an amino acid that increases the modified FGF-1 polypeptide's binding affinity for heparin relative to the binding affinity of SEQ ID NO: 1 to heparin.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully